ArticleBMC infectious diseases2025
Epidemiology of high-risk HPV in Uzbekistan among 44,000 women - genotypes, risk profiles and screening needs in Uzbekistan.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions.
methodsWe analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection.
resultsHigh-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01).
conclusionsUzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.